Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease

Drug Design, Development and Therapy

Volumn 6, Issue , 2012, Pages 43-51

  Nordfjeld, Kim ^a   Andreasen, Hans ^a   Thomsen, Lars L ^a  

^a Pharmacosmos AS   (Denmark)

Author keywords

Inflammatory bowel disease; Iron deficiency anemia; Iron isomaltoside; Iron treatment; Pharmacokinetics

Indexed keywords

IRON; IRON ISOMALTOSIDE 1000; MONOFER; UNCLASSIFIED DRUG; DISACCHARIDE; FERRIC ION;

ABDOMINAL PAIN; ABDOMINAL TENDERNESS; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; CROSSOVER PROCEDURE; CYSTITIS; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; ENTERITIS; FEMALE; FLUSHING; HEADACHE; HORDEOLUM; HUMAN; INJECTION SITE PAIN; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; OUTCOME ASSESSMENT; RHINOPHARYNGITIS; SENSORY DYSFUNCTION; SIDE EFFECT; TACHYCARDIA; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION; XEROSTOMIA; BIOLOGICAL MODEL; CLINICAL TRIAL; DOSE RESPONSE; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; IRON DEFICIENCY ANEMIA; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TISSUE DISTRIBUTION;

ADULT; ANEMIA, IRON-DEFICIENCY; AREA UNDER CURVE; CROSS-OVER STUDIES; DISACCHARIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FERRIC COMPOUNDS; HALF-LIFE; HUMANS; INFLAMMATORY BOWEL DISEASES; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84862253122     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. de Benoist B, McLean E, Egli I, Cogswell M. Worldwide Prevalence of Anaemia 1993-2005: WHO Global Database on Anaemia. Available from http://whqlibdoc.who.int/publications/2008/9789241596657_eng. pdf. Accessed January 11, 2012.
2. Gasche C, Berstad A, Befrits R, et al. Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel. 2007;13(12):1545-1553.
3. Jahn MR, Andreasen HB, Fütterer S, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer®), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm. 2011;78(3):480-491.
4. Medical Dictionary for Regulatory Activities. Maintenance and Support Services Organization, 2010. Available from: http://www.meddramsso. com/. Accessed on January 11, 2012.
5. Lennard-Jones JE, Shivananda S; EC-IBD Study Group. Clinical uniformity of inflammatory bowel disease at presentation and during the first year of disease in the north and south of Europe. Eur J Gastroenterol Hepatol. 1997;9(4):353-359.
6. Seligman PA, Dahl NV, Strobos J, et al. Single-dose pharmacokinetics of sodium ferric gluconate complex in iron-def icient subjects. Pharmacotherapy. 2004;24(5):574-583.
7. Warady BA, Seligman PS, Dahl NV. Single-dosage pharmacokinetics of sodium ferric gluconate complex in iron-deficient pediatric hemodialysis patients. Clin J Am Soc Nephrol. 2007;2(6):1140-1146.
8. Landry R, Jacobs PM, Davis R, Shenouda M, Bolton WK. Pharmacokinetic study of ferumoxytol: a new iron replacement therapy in normal subjects and hemodialysis patients. Am J Nephrol. 2005;25(4):400-410.
9. Pai AB, Nielsen JC, Kausz A, Miller P, Owen JS. Plasma pharmacokinetics of two consecutive doses of ferumoxytol in healthy subjects. Clin Pharmacol Ther. 2010;88(2):237-242.
10. Fütterer S, Andreasen H, Jahn M, Nawroth T, Langguth P. Comparison of nanoparticular iron formulations for parenteral use-are they similar and readily exchangeable? Poster presented at Jahrestagung 2010 der Deutschen Pharmazeutischen Gesellschaft; October 4-7, 2010.
11. Henderson PA, Hillman RS. Characteristics of iron dextran utilization in man. Blood. 1969;34(3):357-375.
12. Danielson BG, Salmonson T, Derendorf H, Geisser P. Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers. Arzneimittelforschung. 1996;46(6):615-621.
13. Danielson BG. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol. 2004;15(Suppl 2):S93-S98.
14. Ferinject, summary of product characteristics, the electronic Medicines Compendium (eMC), updated August 11, 2009. Available from: http:// www.medicines.org.uk/EMC/medicine/24167/SPC/Ferinjectw(ferric(carboxymaltose)/. Accessed January 11, 2012.
15. Australian Public Assessment Report for Ferric Carboxymaltose. TGA May 2011. Available from: http://www.tga.gov.au/pdf/auspar/ausparferric. pdf. Accessed January 11, 2012.
16. Wikström B, Bhandari S, Barany P, et al. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease. J Nephrol. 2011;24(5):589-596.
17. Hildebrandt PR, Bruun NE, Nielsen OW, et al. Effects of administration of iron isomaltoside 1000 in patients with chronic heart failure. A pilot study. Transfus Altern Transfus Med. 2010;11(4):131-137.